MX2021002983A - Agente para tratamiento de trastornos dermatologicos. - Google Patents

Agente para tratamiento de trastornos dermatologicos.

Info

Publication number
MX2021002983A
MX2021002983A MX2021002983A MX2021002983A MX2021002983A MX 2021002983 A MX2021002983 A MX 2021002983A MX 2021002983 A MX2021002983 A MX 2021002983A MX 2021002983 A MX2021002983 A MX 2021002983A MX 2021002983 A MX2021002983 A MX 2021002983A
Authority
MX
Mexico
Prior art keywords
treatment
agent
dermatological disorders
mammal
polypeptide
Prior art date
Application number
MX2021002983A
Other languages
English (en)
Inventor
Gino Villetti
Bruno Pietro Imbimbo
Laura Calzà
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of MX2021002983A publication Critical patent/MX2021002983A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención proporciona un polipéptido no natural para el tratamiento o prevención de trastornos de la piel en un mamífero. La administración del polipéptido es bien tolerada por el mamífero. El polipéptido no natural se proporciona con alta pureza.
MX2021002983A 2018-09-17 2019-09-17 Agente para tratamiento de trastornos dermatologicos. MX2021002983A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18194930 2018-09-17
EP18203665 2018-10-31
PCT/EP2019/074767 WO2020058217A1 (en) 2018-09-17 2019-09-17 Agent for treatment of dermatological disorders

Publications (1)

Publication Number Publication Date
MX2021002983A true MX2021002983A (es) 2021-05-14

Family

ID=67989007

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021002983A MX2021002983A (es) 2018-09-17 2019-09-17 Agente para tratamiento de trastornos dermatologicos.

Country Status (11)

Country Link
US (1) US20220064243A1 (es)
EP (1) EP3852785A1 (es)
JP (1) JP2022502359A (es)
KR (1) KR20210061388A (es)
CN (1) CN113226350A (es)
AU (1) AU2019343514A1 (es)
BR (1) BR112021003820A2 (es)
CA (1) CA3111158A1 (es)
MA (1) MA53636A (es)
MX (1) MX2021002983A (es)
WO (1) WO2020058217A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021318524A1 (en) * 2020-07-27 2023-02-02 Human Cell Co. NGF variants, production, compositions, and therapeutic uses
CA3207296A1 (en) * 2021-01-06 2022-07-14 The Penn State Research Foundation Methods and materials for treating hair loss

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0994188B1 (de) 1998-10-09 2004-01-07 Scil proteins GmbH Verfahren zur Gewinnung von aktivem Beta-NGF
EP1482966B1 (en) 2002-03-12 2014-05-14 Bio-Click Technologies Ltd Method and composition for treating skin wounds with epidermal growth factor
ITRM20060367A1 (it) * 2006-07-13 2008-01-14 Lay Line Genomics Spa Muteine del hngf usi terapeutici e composizioni farmaceutiche
WO2010128519A1 (en) 2009-05-04 2010-11-11 Kumar C Jairaj A method for detecting neuropathy and predicting foot ulcer development in human beings with health conditions like diabetes mellitus
US9617322B2 (en) 2011-12-19 2017-04-11 Wacker Chemie Ag ProNGF mutants and uses thereof in the production of beta-NGF
US20180086805A1 (en) 2016-05-20 2018-03-29 Chiesi Farmaceutici S.P.A. proNGF mutants and uses thereof for the preparation of NGF mutants

Also Published As

Publication number Publication date
US20220064243A1 (en) 2022-03-03
KR20210061388A (ko) 2021-05-27
JP2022502359A (ja) 2022-01-11
CA3111158A1 (en) 2020-03-26
CN113226350A (zh) 2021-08-06
EP3852785A1 (en) 2021-07-28
WO2020058217A1 (en) 2020-03-26
AU2019343514A1 (en) 2021-04-15
MA53636A (fr) 2021-12-22
BR112021003820A2 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
MX2021001439A (es) Composiciones y metodos para el tratamiento de la disfuncion de la glandula de meibomio.
PH12019500845A1 (en) Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof
PH12020551425A1 (en) Rimegepant for cgrp related disorders
MX2021006901A (es) Agentes terapeuticos para enfermedades neurodegenerativas.
PH12019501074A1 (en) Benzenesulfonamide compounds and their use as therapeutic agents
MX2018007074A (es) Moduladores de canales de kv3 para tratar dolor.
PH12018502378A1 (en) Benzenesulfonamide compounds and their use as therapeutic agents
MX2020007049A (es) Peptidos que tienen actividad proteasa para usar en el tratamiento o prevencion de la infeccion por coronavirus.
PH12021550047A1 (en) USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONDRIAL DISORDERS
CO2020005485A2 (es) Administración oral de análogos del péptido glp-1
MX2021002983A (es) Agente para tratamiento de trastornos dermatologicos.
PH12021550122A1 (en) Solubilized apyrases, methods and use
MX2019002901A (es) Tratamiento de esclerosis multiple con chs-131.
MX2022002833A (es) Agente para usarse en el tratamiento o prevencion de trastornos oftalmicos.
MX2016016491A (es) Derivados de o-alquil-bencilidenguanidina y uso terapeutico para el tratamiento de trastornos asociados con acumulacion de proteinas mal plegadas.
ZA202105101B (en) Peptides for treatment and prevention of diabetes and associated disorders
SG10201809099PA (en) Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
EP4219534A3 (en) Methods for treatment of and prophylaxis against inflammatory disorders
MX2020010302A (es) Uso de ácido (1s,3s)-3-amino-4-(difluorometilideno)ciclopentano-1- carboxílico y ácido (s)-3-amino-4-(difluorometilenil)ciclopent-1-e no-1-carboxílico en eltratamiento contra trastornos oculares.
WO2018045371A3 (en) nNIF AND nNIF-RELATED PEPTIDES AND RELATED METHODS
MX2020012940A (es) Metodos de uso de moduladores de empalme.
MX2020003427A (es) Agentes terapeuticos para enfermedades neurodegenerativas.
MX2017014301A (es) Composiciones y metodos para el tratamiento o prevencion de hipertension pulmonar.
MX2019008847A (es) Profarmacos de cisteamina.
NZ747201A (en) (+)-azasetron for use in the treatment of ear disorders